In a recent study Published in frontiers in medicine, Researchers showed that “nearly 90% of patients with dementia suffer from any type of neurobehavioural symptoms and there are no approved medications to treat these symptoms.”
According to the study, neuropsychiatric symptoms (NPS) occur in up to 90% of patients with dementia and are associated with a reduced quality of life
characterized by a progressive decline in “cognitive and functional abilities and challenging behavioral symptoms, is a leading cause of disability and dependency in older adults”.
cannabis treatment
The clinical study aims to evaluate the “safety and effectiveness of the medicinal cannabis oil “Avidekel” for the reduction of behavioral disorders in patients with dementia.”
Results
“There was a statistically significant difference in the proportion of subjects who had a ≥4 point reduction in the Cohen-Mansfield Agitation Inventory score at week 16: 24/40 (60.0%) and 6/20 (30.0% ) for the study and control groups,” the clinical study states.
In addition, the researchers noted that “there was a statistically significant difference in the proportion of subjects who a Cohen-Mansfield Agitation Inventory Score reduction of ≥ 8 points at week 16: 20/40 (50%) and 3/20 (15%), respectively.”
According to the researchersthe treatment was “largely safe, with no significant differences in the occurrence of adverse events between the two groups”.
Of 60 randomized patients: with a mean age of 79.4 years; “36 women (60.0%)]52 (86.7%)” completed the study. According to the researchers, only eight patients in the study group discontinued treatment.
Conclusion:
Finally, the researchers said that their results “suggest that CBD-rich cannabis oil can reduce anxiety in the elderly patients with dementia“One study is not enough to draw conclusions about the safety and efficacy of broad-spectrum CBD,” they added.
“We recommend conducting a…
